Silexion Therapeutics Corp
SLXNHealthcareNASDAQBiotechnology · Last scanned Oct 27, 2026
Scan Results
Daily timeframeSilexion Therapeutics Corp, a clinical-stage biotechnology company, discovers and develops RNA interference (RNAi) therapies for KRAS-driven cancers. At a $2.5M market cap, Silexion Therapeutics Corp ranks as a micro-cap company within healthcare. Its products comprise SIL204 second-generation small interfering RNA (siRNA) undergoing phase 2/3 clinical evaluation for pancreatic cancer and silence mutant KRAS oncogene expression.
Market Cap
$2.5M
Beta
-0.30
P/E (TTM)
—
P/E (Fwd)
-0.27
EPS (TTM)
$-26.75
EPS (Fwd)
$-0.64
ROE
—
ROA
—
Cash
$2.2M
Total Debt
$1.4M
Free CF
—
52W Change
-99.5%
Annual Financials
Cash vs Debt
Where SLXN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SLXN finished 96.27% below its 150-day moving average ($4.02) and 98.03% below its 200-day moving average ($7.63). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SLXN overbought or oversold?
At the October 20, 2026 close, SLXN's RSI(14) was 12.0, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $2.2M in cash and $1.4M in debt, SLXN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating.
The relatively low beta of -0.30 suggests SLXN is a less volatile holding compared to the broader index. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SLXN.